Summerford C, Samulski R J
Gene Therapy Center and Department of Pharmacology, University of North Carolina at Chapel Hill, 27599, USA.
J Virol. 1998 Feb;72(2):1438-45. doi: 10.1128/JVI.72.2.1438-1445.1998.
The human parvovirus adeno-associated virus (AAV) infects a broad range of cell types, including human, nonhuman primate, canine, murine, and avian. Although little is known about the initial events of virus infection, AAV is currently being developed as a vector for human gene therapy. Using defined mutant CHO cell lines and standard biochemical assays, we demonstrate that heparan sulfate proteoglycans mediate both AAV attachment to and infection of target cells. Competition experiments using heparin, a soluble receptor analog, demonstrated dose-dependent inhibition of AAV attachment and infection. Enzymatic removal of heparan but not chondroitin sulfate moieties from the cell surface greatly reduced AAV attachment and infectivity. Finally, mutant cell lines that do not produce heparan sulfate proteoglycans were significantly impaired for both AAV binding and infection. This is the first report that proteoglycan has a role in cellular attachment of a parvovirus. Together, these results demonstrate that membrane-associated heparan sulfate proteoglycan serves as the viral receptor for AAV type 2, and provide an explanation for the broad host range of AAV. Identification of heparan sulfate proteoglycan as a viral receptor should facilitate development of new reagents for virus purification and provide critical information on the use of AAV as a gene therapy vector.
人细小病毒腺相关病毒(AAV)可感染多种细胞类型,包括人类、非人类灵长类动物、犬类、鼠类和禽类。尽管对病毒感染的初始事件了解甚少,但AAV目前正被开发用作人类基因治疗的载体。我们使用特定的突变CHO细胞系和标准生化分析方法,证明硫酸乙酰肝素蛋白聚糖介导了AAV与靶细胞的附着及感染。使用可溶性受体类似物肝素进行的竞争实验表明,其对AAV附着和感染具有剂量依赖性抑制作用。从细胞表面酶解去除硫酸乙酰肝素而非硫酸软骨素部分,可大大降低AAV的附着和感染性。最后,不产生硫酸乙酰肝素蛋白聚糖的突变细胞系在AAV结合和感染方面均受到显著损害。这是关于蛋白聚糖在细小病毒细胞附着中起作用的首次报道。总之,这些结果表明膜相关硫酸乙酰肝素蛋白聚糖作为2型AAV的病毒受体,并为AAV广泛的宿主范围提供了解释。将硫酸乙酰肝素蛋白聚糖鉴定为病毒受体应有助于开发用于病毒纯化的新试剂,并为将AAV用作基因治疗载体提供关键信息。